SEARCH

SEARCH BY CITATION

Abstract

Background

HMG CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, or statins, have been associated with an improvement in outcomes after coronary artery surgery for some time; however, their role in isolated valve surgery (IVS) remains undetermined.

Hypothesis

The pleiotropic effects of statins may produce similar beneficial effects on outcomes after IVS.

Methods

A systematic review of the literature was performed investigating the role of statins in bioprosthetic valve replacement.

Results

Nine observational studies (7 retrospective, 2 prospective) incorporating a total of 18 154 patients were found investigating the role of statin therapy in bioprosthetic valve replacement.

Conclusions

There is presently insufficient evidence to recommend routine statin therapy in IVS, unless concomitant hypercholesterolemia or coronary artery disease is present. A prospective study clearly defining the dose, type, and duration of therapy is now required to finally clarify whether statins alone confer a postoperative benefit in these patients.